Sunday, May 19, 2024
wellness India Expo
Home Tags Syngene

Tag: Syngene

Biocon’s biosimilars revenue crosses milestone of US $1 Billion in FY...

The company garnered an overall revenue of Rs 15,621 Crore in FY24, marking a remarkable 35% growth compared to the previous year

Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr

The company has reported total income of Rs. 933 crores during the period ended March 31, 2024

Syngene biologics manufacturing facility to be soon operational for US &...

New facility to be operational in second half of 2024 includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day

Veeda Clinical Research appoints Dr Mahesh Bhalgat as Group CEO

Prior to joining Veeda, Mahesh was the COO for Syngene International (Biocon Group Company), India’s largest CRO & CDMO company

Biocon clocks Rs 4,519 crore revenue in Q3 of FY24, earns...

The company revenue in biosimilars went up by 65%; research services up by 9%; EBITDA stood at Rs 1,492 Crore, up 106%; Net Profit at Rs 660 Crore

Syngene records Rs 3,193 Crore revenue in FY23, up by 23%

Fourth quarter revenue from operations up 31% to Rs. 994 Crore and PAT up 21% to Rs. 179 Crore

Biocon’s Q3 FY23 revenue stands at Rs 3,020 crore, up by...

The company's revenue from operations surged 35% YoY to Rs 2,941 crore for the third quarter under review, compared with Rs 2,174 crore in the last-year period

Syngene International to acquire stake in O2 Renewable Energy II

A special purpose vehicle (SPV) formed by O2 Energy SG Pte Ltd, for generation and supply of renewable power

Syngene International forms a new subsidiary

The company shall be engaged in the business of manufacturing of pharmaceutical, bio-pharmaceutical and biological products of any kind

Syngene International & Amgen extend their collaboration until 2026

Under the extended contract, the dedicated R&D center, ‘Syngene Amgen Research and Development Center’ (SARC), will continue to conduct drug discovery and development projects as part of Amgen’s global R&D program